Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth set to appeal menopause trial verdict

Wyeth set to appeal menopause trial verdict

18th October 2007

Wyeth has confirmed that it will appeal the verdict in a trial based on patient claims for compensation regarding its Pempro and Premarin hormone drugs.

The ruling, which took place in Nevada, US, saw the judge rule that the pharmaceutical company must pay $134 million (66 million pounds) in compensation to the three plaintiffs, Scofield, Rowatt and Forrester, which includes punitive damages of $99 million.

Wyeth senior vice president Lawrence V Stein was strongly critical of the Nevada trial and confirmed his optimism that that an appeal would be successful.

“The flawed verdict is the result of a trial riddled with errors. The events of last week and the confusion surrounding the jury’s deliberations only confirm our view that this verdict will not survive on appeal,” he said.

Wyeth has denied the accusations by the plaintiffs, who developed cancer after using the drugs, that it has mislead consumers on associated risks, stating that the drug is safe and effective when used as indicated by labels on the drugs.

Six similar cases have so far ruled in the pharmaceutical company’s favour with three resulting in jury verdicts in favour of Wyeth, one saw the plaintiffs’ verdicts overturned and judgment entered in favour of Wyeth and the plaintiffs’ verdicts in the remaining two trials were thrown out and new trials ordered.

Earlier this week Wyeth Pharmaceuticals announced positive study data for desvenlafaxine, with menopausal patients receiving the compound showing reduction in moderate to severe vasomotor symptoms compared to those

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.